Taken together, we demonstrate that HIF1α is a crucial effector on the constitutive activation of AKT through controlling the expression of PDGF-D and PDGFRα in an autocrine and feedforward manner for GBM growth and malignancy, which could be therapeutically targeted by LEM (Fig. 7H). Here, HIF1A is linked to glioblastoma.